Daiichi Sankyo’s new a-fib drug heads toward FDA approval and a crowded market

Damian Garde

A panel of FDA advisers voted in favor of approving Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the in the U.S.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS